Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Alaunos Therapeutics, Inc. (TCRT)

2.0600 -0.0700 (-3.29%)
At close: October 27 at 4:00:00 PM EDT
2.1802 +0.1202 (+5.83%)
Pre-Market: 9:18:22 AM EDT
Chart Range Bar
Loading chart for TCRT
  • Previous Close 2.1300
  • Open 1.8833
  • Bid 1.7600 x 100
  • Ask 2.4000 x 100
  • Day's Range 1.8801 - 2.0800
  • 52 Week Range 0.7200 - 4.5000
  • Volume 377,153
  • Avg. Volume 7,499,489
  • Market Cap (intraday) 7.088M
  • Beta (5Y Monthly) -0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -1.7600
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

www.alaunos.com

1

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TCRT
36.22%
S&P 500 (^GSPC)
12.81%

1-Year Return

TCRT
28.72%
S&P 500 (^GSPC)
12.33%

3-Year Return

TCRT
84.74%
S&P 500 (^GSPC)
87.56%

5-Year Return

TCRT
99.06%
S&P 500 (^GSPC)
69.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY23
Revenue 1k
Earnings -7.84M
Profit Margin -784,300.00%

Q1

FY23

Q2

FY23

Q3

FY23

Q4

FY23

-10M
-8M
-6M
-4M
-2M
0
-600000.0%
-400000.0%
-200000.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -81.13%

  • Return on Equity (ttm)

    -185.95%

  • Revenue (ttm)

    3k

  • Net Income Avi to Common (ttm)

    -4.12M

  • Diluted EPS (ttm)

    -1.7600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    124k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.57M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: